E-viri
Recenzirano
-
Wedemeyer, Heiner; Aleman, Soo; Brunetto, Maurizia Rossana; Blank, Antje; Andreone, Pietro; Bogomolov, Pavel; Chulanov, Vladimir; Mamonova, Nina; Geyvandova, Natalia; Morozov, Viacheslav; Sagalova, Olga; Stepanova, Tatyana; Berger, Annemarie; Manuilov, Dmitry; Suri, Vithika; An, Qi; Da, Ben; Flaherty, John; Osinusi, Anu; Liu, Yang; Merle, Uta; Schulze zur Wiesch, Julian; Zeuzem, Stefan; Ciesek, Sandra; Cornberg, Markus; Lampertico, Pietro
The New England journal of medicine, 07/2023, Letnik: 389, Številka: 1Journal Article
In a randomized trial, 48 weeks of treatment with bulevirtide, which inhibits hepatitis D virus entry into hepatocytes, reduced HDV RNA and alanine aminotransferase levels in patients with chronic hepatitis D.
